الوصف

Expression analysis of androgen synthesis enzymes (e.g., CYP17A1, AKR1C3) in melatonin-treated prostate cancer cells, showing suppression of the intracrine androgen pathway.

Figure 14

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 14: Expression analysis of androgen synthesis enzymes (e.g., CYP17A1, AKR1C3) in melatonin-treated prostate cancer cells, showing suppression of the intracrine androgen pathway.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Expression analysis of androgen synthesis enzymes (e.g., CYP17A1, AKR1C3) in melatonin-treated prostate cancer cells, showing suppression of the intracrine androgen pathway." />
  <figcaption>Figure 14. Expression analysis of androgen synthesis enzymes (e.g., CYP17A1, AKR1C3) in melatonin-treated prostate cancer cells, showing suppression of the intracrine androgen pathway.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

أدلة ذات صلة

Melatonin لـ اضطراب الإيقاع اليوماوي

التقييم A · 176 دراسات